ReceptivaDx™ Test Now Being Used by over 150 IVF Centers
Nationwide; CiceroDx, Inc. Adds Second US Laboratory Site to Meet Demand

February 07, 2018 06:00 AM Eastern Standard Time

HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--CiceroDx, Inc., a women’s healthcare diagnostic company, is pleased to
announce the continued acceptance and use of their signature test,
ReceptivaDx™, designed for women with unexplained infertility. Over 150
IVF centers in the US now offer the test to their patients, many as a
set protocol for patients with unexplained infertility, failed IVF or
recurrent pregnancy loss. In response to the growth, the company has
added PhenoPath Laboratories in Seattle, Washington as an additional
testing site to keep up with demand.

Through a key protein marker, BCL6, the ReceptivaDx™ test helps IVF
centers identify and detect endometriosis, one of the key underlying
causes of unexplained infertility. Centers using the ReceptivaDx™ test
are reporting an increase in success rates in women with a history of
failed IVF and/or recurrent pregnancy loss. When patients test positive,
physicians can then consider surgery or hormone therapy, giving patients
a new pathway towards pregnancy and their goal of starting a family. In
a nine-year study published in the December 2017 issue of Fertility and
Sterility, over 75% of patients with unexplained infertility tested
positive for the BCL6 marker. The positive rate is believed to be even
higher in women with multiple failed transfer attempts.

To meet growing demand, CiceroDx has recently contracted with PhenoPath
Laboratories in Seattle, Washington. PhenoPath is considered one of the
premier immunohistochemistry (IHC) labs in the country. Medical Director
Allen M. Gown, MD, a pioneer in IHC development said, “We are excited to
work with CiceroDx. Our 35 years of experience in IHC combined with
Cicero’s experience will not only provide confidence to the IVF centers,
but will add value to CiceroDx ‘s continued R&D efforts in women’s
health.” CiceroDx announced PhenoPath will also handle international
test volume for ReceptivaDx™ customers located in Australia, New Zealand
and Japan. CiceroDx maintains a 2nd testing US testing center
in Greenville, SC.

With more than six million women in the US affected by infertility
issues, IVF centers across the country seek to help these women conceive
and give birth. Unfortunately, it’s estimated that 15-30% of the women
undergoing infertility evaluation have no cause identified and are less
likely to have a successful IVF experience. According to the American
Society of Reproductive Medicine, endometriosis is associated with
30-50% of all cases of unexplained infertility or over 500,000 cases a
year. With the introduction of the ReceptivaDx™ assay, endometriosis can
be identified quickly and cost effectively using an endometrial biopsy
sample, a procedure routinely performed by IVF centers and Ob-Gyn
offices. Early detection of endometriosis can help guide treatment for
IVF centers to ensure a higher success rate and reduce the number of
cycles required for success.

“The feedback from patients and IVF centers has been tremendous. There
is no better compliment than couples letting us know that our test led
to a pregnancy and successful birth. Before ReceptivaDx™, many of these
families had almost given up hope of achieving that goal,” said Chris
Jackson, CEO and founder of CiceroDx.

CiceroDx is a medical diagnostic company located in Huntington Beach,
California. ReceptivaDx™ is the company’s first test panel in the area
of unexplained infertility and is the exclusive licensed provider of
BCL6 for the detection of endometriosis. Working with IVF centers across
the U.S. and in 15 other countries, CiceroDx intends to expand their
offering globally and is investing in continuing research in the field.